Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib vs Methotrexate in Rheumatoid Arthritis
NCT05827497Phase 4Unknown
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Apr 2023
- Primary completion
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of baricitinib in rheumatoid arthritis (RA) (2 arms), sponsored by Bangabandhu Sheikh Mujib Medical University. Primary endpoint: Disease Activity Score 28-joint count ESR at 24 weeks. Status: unknown.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05827497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05827497.